Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)

NCT06884618 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT06884618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06884618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Recruiting
Start date
April 30, 2025
Completion date
May 25, 2029
Enrollment
405 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms